LP
ABOS icon

LMR Partners’s Acumen Pharmaceuticals ABOS Stock Holding History

LMR Partners’s Portfolio ABOS Stock Details ABOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-11,503
Closed -$46.6K – 1088
2024
Q1 		$46.6K Buy
+11,503
New +$43.4K ﹤0.01% 990
2023
Q3 		– Sell
-14,663
Closed -$70.5K – 928
2023
Q2 		$70.5K Sell
14,663
-2,229
-13% -$10.7K ﹤0.01% 644
2023
Q1 		$68.6K Buy
+16,892
New +$88.2K ﹤0.01% 962
2022
Q4 		– Sell
-10,092
Closed -$101K – 1091
2022
Q3 		$101K Hold
10,092
– – ﹤0.01% 1052
2022
Q2 		$47K Buy
+10,092
New +$37.9K ﹤0.01% 1165

Other funds holding ABOS

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KIA
Knollwood Investment Advisory Hunt Valley, Maryland $992M AUM 28.95% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

LMR Partners's ABOS Position: Q2 2024 in Review

LMR Partners sold out of Acumen Pharmaceuticals (ABOS) in Q2 2024, closing a stake of 11,503 shares — an estimated $46.6K sold.

LMR Partners first reported a position in ABOS in Q2 2022 and held it in 5 quarters. The position peaked at $101K in Q3 2022. 81 funds tracked by Wall St. Rank hold ABOS as of Q2 2024.

  • LMR Partners reported no remaining Acumen Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • LMR Partners sold 11,503 Acumen Pharmaceuticals shares in Q2 2024, an estimated $46.6K.
  • LMR Partners first reported a position in Acumen Pharmaceuticals in Q2 2022 and held it in 5 quarters.
  • LMR Partners's Acumen Pharmaceuticals position peaked at $101K in Q3 2022.
  • 81 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q2 2024.

Based on LMR Partners's 13F filing for Q2 2024, filed 14 Aug 2024.